Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Aptose Biosciences. Inc. (NASDAQ: APTO).

Full DD Report for APTO

You must become a subscriber to view this report.


Recent News from (NASDAQ: APTO)

Aptose to Present New CG'806 Data at the 23rd Congress of the European Hematology Association
SAN DIEGO and TORONTO, May 17, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announ...
Source: GlobeNewswire
Date: May, 17 2018 11:43
Aptose Approaching The Clinic With 2 Very Interesting Assets
It has been a long road, but Aptose ( APTO ) is closing in on getting its two lead drugs into clinical trials. The company still has to resolve a manufacturing-related clinical hold for APTO-253 and finish its pre-IND work on CG’806, but Aptose should have both compounds in human test...
Source: SeekingAlpha
Date: May, 17 2018 07:45
Aptose Biosciences' (APTO) CEO William Rice on Q1 2018 Results - Earnings Call Transcript
Aptose Biosciences Inc. (APTO) Q1 2018 Earnings Conference Call May 10, 2018 17:00 P.M. ET Executives Susan Pietropaolo - SMP Communications William G. Rice - Chairman, President, and CEO Gregory Chow - SVP and CFO Analysts John Newman - Canaccord Genuity Joseph Pantginis...
Source: SeekingAlpha
Date: May, 10 2018 20:32
Aptose Biosciences misses by $0.11
Aptose Biosciences (NASDAQ: APTO ): Q1 EPS of -$0.23 misses by $0.11 . More news on: Aptose Biosciences Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 10 2018 16:19
Aptose Reports Results for the First Quarter Ended March 31, 2018
SAN DIEGO and TORONTO, May 10, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today anno...
Source: GlobeNewswire
Date: May, 10 2018 16:00
Free Technical Insights on Aimmune Therapeutics and Three More Biotech Stocks
Stock Research Monitor: APHB, APTO, and ABIO LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want a free Stock Review on AIMT sign up now at www.wallstequities.com/registration . On Wednesday, benchmark US indices were in bullish colors as the NASDAQ Composite closed the trading ...
Source: ACCESSWIRE IA
Date: May, 10 2018 07:15
Aptose Exercises Early Option for CG-806 License From CrystalGenomics
SAN DIEGO and SEOUL, South Korea, May 07, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) and CrystalGenomics, Inc. (KOSDAQ:083790) today announced that Aptose exercised its option under the 2016 Option Agreement to exclusively license CG-806, a first-in-class, non-...
Source: GlobeNewswire
Date: May, 07 2018 07:00
Aptose To Release First Quarter Ended March 31, 2018 Financial Results and Hold Conference Call on May 10, 2018
SAN DIEGO and TORONTO, May 01, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of p...
Source: GlobeNewswire
Date: May, 01 2018 07:30
Aptose Announces Appointment of Caroline M. Loewy to Board of Directors
SAN DIEGO and TORONTO, April 25, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the appointment of Caroline M. Loewy to the Board ...
Source: GlobeNewswire
Date: April, 25 2018 07:00
Aptose to Present at the Bloom Burton & Co. Healthcare Investor Conference 2018
SAN DIEGO and TORONTO, April 24, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today an...
Source: GlobeNewswire
Date: April, 24 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-153.112.953.132.9385,940
2018-08-143.0053.103.16632.961684,418
2018-08-133.013.023.062.8091,536
2018-08-103.033.0153.153.00161,018
2018-08-092.773.073.122.75221,254

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-149,46024,61638.4303Short
2018-08-136,76130,18922.3956Cover
2018-08-1022,76242,76053.2320Short
2018-08-0956,398105,73153.3410Short
2018-08-0836,243224,46016.1468Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on APTO.


About Aptose Biosciences. Inc. (NASDAQ: APTO)

Logo for Aptose Biosciences. Inc. (NASDAQ: APTO)

Lorus is a clinical stage cancer drug development company with a strong commitment to discovering and developing innovative molecular targeted therapies addressing major unmet medical needs.

 

Contact Information

 

 

Current Management

  • William G. Rice / President
  • Greg Chow / CFO
  • Saeid Babaei / VP, Bus. Affairs
  • Elizabeth Williams / IR

Current Share Structure

  • Market Cap: $92,131,878 - 05/14/2018
  • Issue and Outstanding: 27,502,053 - 12/31/2017

 


Recent Filings from (NASDAQ: APTO)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 17 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 10 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 10 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 09 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 07 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 01 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 25 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 24 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 17 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 16 2018

 

 


Daily Technical Chart for (NASDAQ: APTO)

Daily Technical Chart for (NASDAQ: APTO)


Stay tuned for daily updates and more on (NASDAQ: APTO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: APTO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in APTO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of APTO and does not buy, sell, or trade any shares of APTO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/